MFN2 Antibody (monoclonal) (M03)
Mouse monoclonal antibody raised against a partial recombinant MFN2.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, E |
---|---|
Primary Accession | O95140 |
Other Accession | NM_014874 |
Reactivity | Human, Rat |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG2a Kappa |
Clone Names | 4H8 |
Calculated MW | 86402 Da |
Gene ID | 9927 |
---|---|
Other Names | Mitofusin-2, 365-, Transmembrane GTPase MFN2, MFN2, CPRP1, KIAA0214 |
Target/Specificity | MFN2 (NP_055689, 661 a.a. ~ 757 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | MFN2 Antibody (monoclonal) (M03) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a mitochondrial membrane protein that participates in mitochondrial fusion and contributes to the maintenance and operation of the mitochondrial network. This protein is involved in the regulation of vascular smooth muscle cell proliferation, and it may play a role in the pathophysiology of obesity. Mutations in this gene cause Charcot-Marie-Tooth disease type 2A2, and hereditary motor and sensory neuropathy VI, which are both disorders of the peripheral nervous system. Defects in this gene have also been associated with early-onset stroke. Two transcript variants encoding the same protein have been identified.
References
1.Exercise training can induce cardiac autophagy at end-stage chronic conditions: Insights from a graft-versus-host-disease mouse model.Fiuza-Luces C, Delmiro A, Soares-Miranda L, Gonzalez-Murillo A, Martinez-Palacios J, Ramirez M, Lucia A, Moran MBrain Behav Immun. 2013 Nov 14. pii: S0889-1591(13)00538-2. doi: 10.1016/j.bbi.2013.11.007.2.Regulation of miRNAs in human skeletal muscle following acute endurance exercise and short term endurance training.Russell AP, Lamon S, Boon H, Wada S, Guller I, Brown EL, Chibalin AV, Zierath J, Snow RJ, Stepto NK, Wadley GD, Akimoto TJ Physiol. 2013 Jun 24.3.Over-expressing mitofusin-2 in healthy mature Mammalian skeletal muscle does not alter mitochondrial bioenergetics.Lally JS, Herbst EA, Matravadia S, Maher AC, Perry CG, Ventura-Clapier R, Holloway GPPLoS One. 2013;8(1):e55660. doi: 10.1371/journal.pone.0055660. Epub 2013 Jan 31.4.Mitofusin-2 independent juxtaposition of endoplasmic reticulum and mitochondria: an ultrastructural study.Cosson P, Marchetti A, Ravazzola M, Orci L.PLoS One. 2012;7(9):e46293. doi: 10.1371/journal.pone.0046293. Epub 2012 Sep 28.5.Mitochondrial bioenergetics and dynamics interplay in complex i-deficient fibroblasts.Moran M, Rivera H, Sanchez-Arago M, Blazquez A, Merinero B, Ugalde C, Arenas J, Cuezva JM, Martin MA.Biochim Biophys Acta. 2010 May;1802(5):443-453. Epub 2010 Feb 11.6.PGC1{alpha} relationship with skeletal muscle palmitate oxidation is not present with obesity, despite maintained ained PGC1{alpha} and PGC1{beta} protein.Holloway GP, Perry CG, Thrush AB, Heigenhauser GJ, Dyck DJ, Bonen A, Spriet LL.Am J Physiol Endocrinol Metab. 2008 Jun;294(6):E1060-9. Epub 2008 Mar 18.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.